Puma Biotechnology Files 8-K Report
Ticker: PBYI · Form: 8-K · Filed: May 17, 2024 · CIK: 1401667
| Field | Detail |
|---|---|
| Company | Puma Biotechnology, Inc. (PBYI) |
| Form Type | 8-K |
| Filed Date | May 17, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $107.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, regulatory-filing, corporate-events
TL;DR
Puma Biotech filed an 8-K, no major news yet.
AI Summary
On May 17, 2024, Puma Biotechnology, Inc. filed an 8-K report to disclose other events. The filing does not contain specific details regarding new agreements, material events, or financial figures, but serves as a notification of ongoing corporate activities.
Why It Matters
This filing indicates that Puma Biotechnology is actively managing its corporate affairs and complying with regulatory reporting requirements.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain information that inherently increases risk for investors.
Key Players & Entities
- PUMA BIOTECHNOLOGY, INC. (company) — Registrant
- May 17, 2024 (date) — Date of earliest event reported
- 10880 Wilshire Blvd, Suite 2150 Los Angeles, CA 90024 (address) — Principal executive offices
FAQ
What specific event triggered this 8-K filing?
The filing states 'Other Events' as the item information, indicating a material event occurred that requires disclosure, but the specific nature of the event is not detailed in the provided text.
When was the report filed and what is the earliest event date?
The report was filed on May 17, 2024, and the earliest event reported is also May 17, 2024.
What is Puma Biotechnology's primary business?
Puma Biotechnology, Inc. is in the business of Pharmaceutical Preparations, as indicated by its SIC code [2834].
What is the company's principal executive office address?
The principal executive offices are located at 10880 Wilshire Blvd, Suite 2150, Los Angeles, CA 90024.
Has the company changed its name or address recently?
The filing notes a former company name of 'INNOVATIVE ACQUISITIONS CORP' with a date of name change as June 1, 2007, but does not indicate any recent changes.
Filing Stats: 855 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2024-05-17 16:43:17
Key Financial Figures
- $0.0001 — on which registered Common Stock , $0.0001 par value per share PBYI The Nasdaq
- $107.5 million — and not invalid, and awarded Plaintiffs $107.5 million in damages for past acts of infringemen
Filing Documents
- pbyi20240517_8k.htm (8-K) — 29KB
- 0001437749-24-017504.txt ( ) — 159KB
- pbyi-20240517.xsd (EX-101.SCH) — 3KB
- pbyi-20240517_def.xml (EX-101.DEF) — 11KB
- pbyi-20240517_lab.xml (EX-101.LAB) — 15KB
- pbyi-20240517_pre.xml (EX-101.PRE) — 11KB
- pbyi20240517_8k_htm.xml (XML) — 3KB
01
Item 8.01. Other Events On September 22, 2021, Puma Biotechnology, Inc. (the "Company") and Wyeth LLC ("Wyeth"), as co-plaintiffs, filed suit against AstraZeneca Pharmaceuticals, LP, AstraZeneca AB (together "AstraZeneca"), and AstraZeneca PLC for infringement of United States Patent Nos. 10,603,314 ("the '314 patent") and 10,596,162 ("the '162 patent") ( Puma Biotechnology, Inc. et al. v. AstraZeneca Pharmaceuticals LP et al. , 1:21CV01338 (D. Del. Sep. 22, 2021) (the "AstraZeneca Litigation")). The Company's complaint alleges that AstraZeneca's commercial manufacture, use, offer for sale, sale, distribution, and/or importation of Tagrisso (osimertinib) products for the treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancer infringes the '314 and '162 patents. The Company is an exclusive licensee of the '314 and '162 patents under the Pfizer Agreement. Plaintiffs seek a judgment that AstraZeneca's product infringes the asserted patents and an award of monetary damages in an amount to be proven at trial. AstraZeneca filed an answer and counterclaims on November 5, 2021, including claims challenging the asserted patents as not infringed and/or invalid, and accusing plaintiffs of unclean hands and patent misuse. On March 18, 2024, the court denied AstraZeneca's motion for invalidity, denied AstraZeneca's motion for summary judgment of non-infringement, except as to pre-issuance damages, and denied AstraZeneca's motion for summary judgment on its advice of counsel defense. The court denied the plaintiffs' and defendants' motion to exclude certain expert testimony. AstraZeneca also moved to dismiss both the Company and Wyeth as plaintiffs for lack of constitutional standing. The court denied the motion to dismiss with respect to Wyeth and granted the motion with respect to the Company. The Company was dismissed as a plaintiff in the matter by order dated March 18, 2024. AstraZeneca subsequently moved to dismiss its counterclaims against the Co
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, Puma Biotechnology, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 17, 2024 PUMA BIOTECHNOLOGY, INC. a Delaware Corporation By: /s/ Alan Auerbach Name: Alan H. Auerbach Title: Chief Executive Officer, President and Chairman of the Board